TherapeuticsMD Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . TherapeuticsMD
TXMD Stock  USD 2.50  0.27  12.11%   
TherapeuticsMD's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing TherapeuticsMD's valuation are provided below:
Gross Profit
2.8 M
Profit Margin
0.108
Market Capitalization
28.9 M
Enterprise Value Revenue
10.1925
Revenue
2.8 M
There are over one hundred nineteen available fundamental trend indicators for TherapeuticsMD, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of TherapeuticsMD's current performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 315.2 M. The current year's Enterprise Value is expected to grow to about 474.1 M

TherapeuticsMD Total Revenue

1.92 Million

Check TherapeuticsMD financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TherapeuticsMD's main balance sheet or income statement drivers, such as Depreciation And Amortization of 363.7 K, Interest Expense of 10.4 K or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.088 or PTB Ratio of 0.34. TherapeuticsMD financial statements analysis is a perfect complement when working with TherapeuticsMD Valuation or Volatility modules.
  
Build AI portfolio with TherapeuticsMD Stock
Check out the analysis of TherapeuticsMD Correlation against competitors.
For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.

TherapeuticsMD Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding13.9 M13.3 M6 M
Slightly volatile
Total Assets53.3 M44.6 M93.4 M
Pretty Stable
Other Current Liabilities3.6 M3.8 M14 M
Slightly volatile
Total Current Liabilities5.6 M5.9 M31.8 M
Pretty Stable
Property Plant And Equipment Net7.4 M7 M4.1 M
Slightly volatile
Accounts Payable281.9 K296.7 K5.6 M
Very volatile
Cash5.5 M5.8 M56.3 M
Very volatile
Non Current Assets Total34.9 M33.2 M21.6 M
Slightly volatile
Cash And Short Term Investments5.5 M5.8 M56.3 M
Very volatile
Net Receivables4.9 M4.1 M8.2 M
Slightly volatile
Common Stock Total Equity519.2 K494.5 K275.2 K
Slightly volatile
Liabilities And Stockholders Equity53.3 M44.6 M93.4 M
Pretty Stable
Inventory9.2 M8.8 M4.7 M
Slightly volatile
Other Stockholder Equity1.2 B1.1 B582.1 M
Slightly volatile
Total Liabilities12.5 M13.2 M65.5 M
Pretty Stable
Property Plant And Equipment Gross7.4 M7 M4.3 M
Slightly volatile
Total Current Assets10.8 M11.4 M71.4 M
Very volatile
Common Stock12 K12.7 K118.2 K
Slightly volatile
Short and Long Term Debt Total7.8 M8.3 M66.9 M
Very volatile
Non Currrent Assets Other4.8 M2.8 M5.3 M
Slightly volatile
Short Term Debt1.8 M1.9 M12.6 M
Pretty Stable
Other Assets1.091.153.2 M
Very volatile
Capital Surpluse1.2 B1.1 B576.3 M
Slightly volatile
Intangible Assets4.7 M5 M9 M
Pretty Stable
Property Plant Equipment10.3 K10.8 K974.9 K
Very volatile
Other Liabilities1.8 K1.9 K28.2 K
Slightly volatile
Long Term Debt Total140.1 M273.4 M132.2 M
Slightly volatile
Non Current Liabilities Other636.1 K669.6 K4.5 M
Pretty Stable
Net Invested Capital23.4 M24.6 M103.7 M
Slightly volatile
Capital Stock9.4 K9.9 K189.1 K
Slightly volatile
Capital Lease Obligations7.1 M6.5 M9.6 M
Slightly volatile
Short and Long Term Debt150.6 M169.4 M184.9 M
Slightly volatile

TherapeuticsMD Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization363.7 K585.4 K602.1 K
Slightly volatile
Selling General Administrative5.2 M5.5 M36.3 M
Pretty Stable
Total Revenue1.9 M2 M17.4 M
Pretty Stable
Gross Profit1.9 M2 M14.7 M
Pretty Stable
Other Operating Expenses7.1 M7.5 M70 M
Very volatile
Cost Of Revenue556.1 K585.4 K2.9 M
Very volatile
Total Operating Expenses7.1 M7.5 M67.2 M
Very volatile
Selling And Marketing Expenses1.3 M1.4 M54 M
Very volatile
Research Development4.7 M5 M18.4 M
Pretty Stable
Reconciled Depreciation556.1 K585.4 K881.6 K
Slightly volatile

TherapeuticsMD Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow4.7 M5 M56.6 M
Pretty Stable
End Period Cash Flow5.5 M5.8 M57 M
Very volatile
Depreciation580.8 K585.4 K644.1 K
Slightly volatile
Stock Based Compensation288.4 K303.6 K7 M
Pretty Stable
Change To Netincome12.6 M23.5 M13.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.825.0736.9267
Slightly volatile
Dividend Yield0.0880.10.1121
Slightly volatile
Days Sales Outstanding698664590
Slightly volatile
Average Payables19.8 M18.9 M12.8 M
Slightly volatile
Stock Based Compensation To Revenue0.180.190.7185
Slightly volatile
Capex To Depreciation49.3446.9920.3996
Slightly volatile
EV To Sales5.846.1538.6732
Slightly volatile
Inventory Turnover0.20.211.5346
Slightly volatile
Days Of Inventory On Hand1.9 K1.8 K848
Slightly volatile
Payables Turnover0.710.741.0494
Slightly volatile
Sales General And Administrative To Revenue0.710.742.9785
Very volatile
Average Inventory1.2 M1.2 M1.1 M
Slightly volatile
Research And Ddevelopement To Revenue0.180.16081.02
Slightly volatile
Capex To Revenue34.9433.288.5172
Slightly volatile
Cash Per Share0.480.521.2389
Slightly volatile
Days Payables Outstanding383508659
Pretty Stable
Intangibles To Total Assets0.120.130.1114
Pretty Stable
Current Ratio2.12.214.071
Slightly volatile
Receivables Turnover0.540.577.7253
Slightly volatile
Capex Per Share5.045.318.9414
Slightly volatile
Average Receivables32.4 M30.9 M15.9 M
Slightly volatile
Revenue Per Share0.170.1841.8964
Slightly volatile
Interest Debt Per Share0.680.7222.3623
Slightly volatile
Debt To Assets0.160.170.4936
Pretty Stable
Graham Number28.1829.67139
Slightly volatile
Operating Cycle421664856
Pretty Stable
Days Of Payables Outstanding383508659
Pretty Stable
Ebt Per Ebit0.540.571.0758
Slightly volatile
Long Term Debt To Capitalization1.981.881.248
Slightly volatile
Total Debt To Capitalization0.180.190.8879
Slightly volatile
Quick Ratio2.12.213.839
Slightly volatile
Net Income Per E B T0.80.847.8234
Pretty Stable
Cash Ratio1.071.133.0576
Slightly volatile
Days Of Inventory Outstanding1.9 K1.8 K848
Slightly volatile
Days Of Sales Outstanding698664590
Slightly volatile
Fixed Asset Turnover0.250.2641.1954
Slightly volatile
Debt Ratio0.160.170.4936
Pretty Stable
Price Sales Ratio4.825.0736.9267
Slightly volatile
Asset Turnover0.04960.05220.2984
Slightly volatile
Gross Profit Margin0.930.880.7938
Slightly volatile

TherapeuticsMD Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap315.2 M300.2 M592.6 M
Slightly volatile
Enterprise Value474.1 M451.5 M643.5 M
Slightly volatile

TherapeuticsMD Fundamental Market Drivers

Forward Price Earnings2.291
Cash And Short Term Investments5.1 M

TherapeuticsMD Upcoming Events

5th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View

About TherapeuticsMD Financial Statements

TherapeuticsMD stakeholders use historical fundamental indicators, such as TherapeuticsMD's revenue or net income, to determine how well the company is positioned to perform in the future. Although TherapeuticsMD investors may analyze each financial statement separately, they are all interrelated. For example, changes in TherapeuticsMD's assets and liabilities are reflected in the revenues and expenses on TherapeuticsMD's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in TherapeuticsMD. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.2 M1.1 M
Total Revenue2 M1.9 M
Cost Of Revenue585.4 K556.1 K
Stock Based Compensation To Revenue 0.19  0.18 
Sales General And Administrative To Revenue 0.74  0.71 
Research And Ddevelopement To Revenue 0.16  0.18 
Capex To Revenue 33.28  34.94 
Revenue Per Share 0.18  0.17 
Ebit Per Revenue(3.11)(3.26)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft
When determining whether TherapeuticsMD is a strong investment it is important to analyze TherapeuticsMD's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact TherapeuticsMD's future performance. For an informed investment choice regarding TherapeuticsMD Stock, refer to the following important reports:
How To Invest In TherapeuticsMD
Details
Is TherapeuticsMD Stock a good investment?
Details
What is TherapeuticsMD's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of TherapeuticsMD Correlation against competitors.
For information on how to trade TherapeuticsMD Stock refer to our How to Trade TherapeuticsMD Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TherapeuticsMD. If investors know TherapeuticsMD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TherapeuticsMD listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.01
Revenue Per Share
0.242
Quarterly Revenue Growth
0.433
Return On Assets
(0.03)
Return On Equity
0.0027
The market value of TherapeuticsMD is measured differently than its book value, which is the value of TherapeuticsMD that is recorded on the company's balance sheet. Investors also form their own opinion of TherapeuticsMD's value that differs from its market value or its book value, called intrinsic value, which is TherapeuticsMD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TherapeuticsMD's market value can be influenced by many factors that don't directly affect TherapeuticsMD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between TherapeuticsMD's value and its price as these two are different measures arrived at by different means. Investors typically determine if TherapeuticsMD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TherapeuticsMD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY